Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5183252
Max Phase: Preclinical
Molecular Formula: C135H199N37O42
Molecular Weight: 3012.29
Associated Items:
ID: ALA5183252
Max Phase: Preclinical
Molecular Formula: C135H199N37O42
Molecular Weight: 3012.29
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)O)C(C)C)C(N)=O
Standard InChI: InChI=1S/C135H199N37O42/c1-65(2)50-88(110(141)191)158-123(204)94(56-75-59-148-80-27-17-16-26-78(75)80)163-118(199)86(41-45-102(140)183)157-131(212)107(67(5)6)171-126(207)92(52-71-22-12-10-13-23-71)162-124(205)95(57-105(187)188)164-117(198)85(40-44-101(139)182)151-111(192)68(7)150-114(195)82(29-20-48-146-134(142)143)153-115(196)83(30-21-49-147-135(144)145)155-129(210)98(63-175)168-125(206)96(58-106(189)190)165-120(201)89(51-66(3)4)159-121(202)90(54-73-31-35-76(179)36-32-73)160-116(197)81(28-18-19-47-136)154-128(209)97(62-174)167-122(203)91(55-74-33-37-77(180)38-34-74)161-119(200)87(42-46-104(185)186)156-130(211)99(64-176)169-133(214)109(70(9)178)172-127(208)93(53-72-24-14-11-15-25-72)166-132(213)108(69(8)177)170-103(184)60-149-113(194)84(39-43-100(138)181)152-112(193)79(137)61-173/h10-17,22-27,31-38,59,65-70,79,81-99,107-109,148,173-180H,18-21,28-30,39-58,60-64,136-137H2,1-9H3,(H2,138,181)(H2,139,182)(H2,140,183)(H2,141,191)(H,149,194)(H,150,195)(H,151,192)(H,152,193)(H,153,196)(H,154,209)(H,155,210)(H,156,211)(H,157,212)(H,158,204)(H,159,202)(H,160,197)(H,161,200)(H,162,205)(H,163,199)(H,164,198)(H,165,201)(H,166,213)(H,167,203)(H,168,206)(H,169,214)(H,170,184)(H,171,207)(H,172,208)(H,185,186)(H,187,188)(H,189,190)(H4,142,143,146)(H4,144,145,147)/t68-,69+,70+,79-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,107-,108-,109-/m0/s1
Standard InChI Key: LCPUAJWQZPHSID-CMHKWSRRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3012.29 | Molecular Weight (Monoisotopic): 3010.4573 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Li L, Dai S, Liu JY, Wu W, Zhao QX, Wang X, Wang N, Xu ZH.. (2022) Antagonistic Effect and In Vitro Activity of Dauricine on Glucagon Receptor., 85 (8.0): [PMID:35834753] [10.1021/acs.jnatprod.2c00446] |
Source(1):